Results 121 to 130 of about 15,602,619 (166)
Some of the next articles are maybe not open access.
Antibodies to Hepatitis A and B Virus Antigens in Rho (D) Immune Globulin.
Lancet, The, 1985G, Höltz, R, von Lohr, H, Mengel
exaly +5 more sources
Blood, 2005
Abstract The Food and Drug Administration (FDA) licensed Rho(D) immune globulin intravenous (anti-D IGIV) on March 24, 1995, for treatment of immune thrombocytopenic purpura (ITP). A previous review described data on 15 patients who experienced acute hemoglobinemia or hemoglobinuria following anti-D IGIV administration for ITP or ...
exaly +2 more sources
Abstract The Food and Drug Administration (FDA) licensed Rho(D) immune globulin intravenous (anti-D IGIV) on March 24, 1995, for treatment of immune thrombocytopenic purpura (ITP). A previous review described data on 15 patients who experienced acute hemoglobinemia or hemoglobinuria following anti-D IGIV administration for ITP or ...
exaly +2 more sources
Transfusion
Abstract Background Rho(D) immune globulin (RhIg) is used to reduce RhD alloimmunization in pregnancy. This study describes potential causes for RhD alloimmunization after the development and implementation of RhIg.
Carolina Bonet Bub +2 more
exaly +3 more sources
Abstract Background Rho(D) immune globulin (RhIg) is used to reduce RhD alloimmunization in pregnancy. This study describes potential causes for RhD alloimmunization after the development and implementation of RhIg.
Carolina Bonet Bub +2 more
exaly +3 more sources
Blood, 2000
AbstractRho(D) immune globulin intravenous (anti-D IGIV) was licensed by the United States Food and Drug Administration (FDA) in March 1995 to treat patients with immune thrombocytopenic purpura (ITP). Anti-D IGIV induces extravascular hemolysis, an expected adverse reaction that is consistent with the presumed mechanism of action.
exaly +3 more sources
AbstractRho(D) immune globulin intravenous (anti-D IGIV) was licensed by the United States Food and Drug Administration (FDA) in March 1995 to treat patients with immune thrombocytopenic purpura (ITP). Anti-D IGIV induces extravascular hemolysis, an expected adverse reaction that is consistent with the presumed mechanism of action.
exaly +3 more sources
Rho (D) Immune Globulin (Human)
JAMA, 1968Rh O (D) immune globulin (RhoGAM) was administered to Rh negative women within 72 hours after they had given birth to Rh positive, ABO compatible infants to prevent Rh immunization. Two studies, differing only in the dose of anti-Rh immune globulin administered, have shown almost complete prevention of Rh immunization whereas in a group of Rh negative ...
openaire +1 more source
Rho (D) immune globulin in the emergency department
Journal of the American College of Emergency Physicians, 1975Many patients with spontaneous abortion receive definitive treatment in the emergency department. A part of treatment should include administration of Rh o (D) immune globulin (human) to patients who are Rh o (D) negative and Du negative (except when the husband is known to be Rh o (D) negative and Du negative).
openaire +1 more source
Postgraduate Medicine, 1984
PreviewTypically, Rho(D) immune globulin is used in Rho(D)-negative women after delivery of an Rho(D)-positive infant. However, there are other specific circumstances in which use of this agent, which has had a dramatic impact on the incidence of hemolytic disease in newborns, can prevent sensitization.
openaire +2 more sources
PreviewTypically, Rho(D) immune globulin is used in Rho(D)-negative women after delivery of an Rho(D)-positive infant. However, there are other specific circumstances in which use of this agent, which has had a dramatic impact on the incidence of hemolytic disease in newborns, can prevent sensitization.
openaire +2 more sources
Position statement on Rho(d) immune globulin Administration in the first trimester
Fertility and SterilityASRM supports the recommendations in the 2024 American College of Obstetricians and Gynecologists Clinical Practice Update regarding Rho(d) immune globulin administration in the first trimester.
Clarissa Gracia +13 more
openaire +2 more sources
Rho(D) immune globulin shortage and fetal Rh(D) screening with cell-free DNA
Current Opinion in Obstetrics & GynecologyPurpose of review Despite the availability of Rh(D) immune globulin (RhIg) to prevent alloimmunization in Rh(D)-negative pregnant patients, anti-Rh(D) alloimmunization remains a prevalent cause of hemolytic disease of the fetus and newborn (HDFN).
Matthew R, Grace +2 more
openaire +2 more sources
The Journal of Maternal-Fetal & Neonatal Medicine, 2007
This study evaluated the relationship between prenatal mercury exposure from thimerosal (49.55% mercury by weight)-containing Rho(D)-immune globulins (TCRs) and autism spectrum disorders (ASDs).The Institutional Review Board of the Institute for Chronic Illnesses approved the present study.
David A, Geier, Mark R, Geier
openaire +2 more sources
This study evaluated the relationship between prenatal mercury exposure from thimerosal (49.55% mercury by weight)-containing Rho(D)-immune globulins (TCRs) and autism spectrum disorders (ASDs).The Institutional Review Board of the Institute for Chronic Illnesses approved the present study.
David A, Geier, Mark R, Geier
openaire +2 more sources

